Investigating the effect of nasal dexmedetomidine and midazolam in children undergoing neurosurgery on anxiety before and and pain levels after surgery.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200518047491N2

Enrollment

Registered

2025-04-07

Start date

2024-03-20

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pre-operative and post-operative levels of anxiety and pain.".

Interventions

Intervention 1: Intervention group:In the dexmedetomidine (DEX) group, patients received 2 mcg/kg of intranasal dexmedetomidine diluted with sterile water to a total volume of 2 cc in an unlabeled syr

Eligibility

Sex/Gender

All

Age

No minimum to 18 Years

Inclusion criteria

Inclusion criteria: Children undergoing Neurosurgery

Exclusion criteria

Exclusion criteria: Parents didn’t agree to participate Patients ASA class 3 & 4

Design outcomes

Primary

Measure	Time frame
In comparison to midazolam, dexmedetomidine demonstrated superior efficacy in managing postoperative emergence agitation in pediatric patients. We recommend conducting further studies to investigate the advantages and disadvantages of dexmedetomidine and to compare its efficacy with other sedative agents. Timepoint: Before and After induction of anesthesia and after surgery. Method of measurement: questionnaire.	—

Measure

Time frame

In comparison to midazolam, dexmedetomidine demonstrated superior efficacy in managing postoperative emergence agitation in pediatric patients. We recommend conducting further studies to investigate the advantages and disadvantages of dexmedetomidine and to compare its efficacy with other sedative agents. Timepoint: Before and After induction of anesthesia and after surgery. Method of measurement: questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNastaran Sadat Mahdavi

Shahid Beheshti University of Medical Sciences

nasimahdavi@sbmu.ac.ir+98 21 2222 7021

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026